News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Ben discusses when publication-only or publication-plus makes sense with respect to research findings.
The technology, now in preclinical development, has the potential to overcome the limitations of traditional cancer treatments for solid tumors.
These findings suggest OPGx-LCA5, Opus Genetics' investigational gene augmentation therapy, could improve vision for patients previously considered untreatable.
Its novel gene therapy for spinal muscular atrophy type 1 (SMA1) has been cleared for clinical trial in Brazil by ANVISA.
Rese-cel is an experimental CAR T-cell therapy designed to “reset” the immune system in people with autoimmune diseases.
Now being tested in a clinical trial at Penn, the device aims to reduce infant stress, support bonding, and potentially improve growth and feeding for preterm babies.
Avisi treated its first patient in a clinical trial to evaluate the safety and effectiveness of its novel VisiPlate® glaucoma treatment device.
BlueWhale Bio was co-founded by Carl June, MD, the Richard W. Vague Professor in Immunotherapy and James Riley, PhD, Professor of Microbiology, both at Penn Medicine.
On December 2, PCI celebrated Penn researchers and innovators named as inventors on patents issued to Penn this past fiscal year.
Penn announced the launch of its StartUP Fund.